Publication
  • EHA •
  • 13 June, 2026 •
  • •

Avatrombopag in TPO RA–naive adults in acute, persistent, and chronic phases of ITP: results from the REAL AVA 3.0 retrospective study

Sandhya Panch, Abiola Oladapo, Faizan Sattar, Michael Vredenburg , Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Debbie Jiang

Publication
  • EHA •
  • 12 June, 2026 •
  • •

Impact of protocol mandated dose holds on platelet response durability in pediatric ITP treated with avatrombopag: AVA 301 post hoc analysis

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian D. Jamieson, Chelsea Bernheisel, Michael Vredenburg , Faizan Sattar

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Patient-reported outcomes of avatrombopag for chronic immune thrombocytopenia: Interim analysis of the Phase 4 adopt study

María Eva Mingot Castellano, María Teresa Álvarez Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Jessica Zhang, Viridiana Cano Garcia, Nina Skuban

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Real-world treatment patterns & outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the real-AVA 3.5 study

Caroline Piatek, Abiola Oladapo, Scott Kolodny, Michael Vredenburg , Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Hillary Maitland

Sign up for alerts